As tests evolve and costs of cancer care rise: Reappraising stool-based screening for colorectal neoplasia

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 8, 2008, Pages 697-712

  Parekh, M ^a,b   Fendrick, A M ^c,d   Ladabaum, U ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; FECES ANALYSIS; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; MONTE CARLO METHOD; OCCULT BLOOD; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FECES; HUMANS; MARKOV CHAINS; MASS SCREENING; OCCULT BLOOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 40949133413     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03632.x     Document Type: Article

References (98)

1. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003 53:44 55.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55:10 30.
3. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 137:132 41.
4. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002 137:96 104.
5. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990 113:373 84.
6. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995 109:1781 90.
7. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000 284:1954 61.
8. Sonnenberg A, Delco F, Inadomi J. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000 133:573 84.
9. Wagner JL, Tunis S, Brown M, Ching A, Almeida R. Cost-effectiveness of colorectal cancer screening in average risk adults. In:Young G, Rozen P, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. Philadelphia:WB Saunders, 1996:321 56.
10. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997 112:594 642.
11. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001 135:769 81.
12. Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001 111:593 601.
13. Khandker RK, Dulski JD, Kilpatrick JB, Ellis RP, Mitchell JB, Baine WB. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000 16:799 810.
14. Chao A, Connell CJ, Cokkinides V, Jacobs EJ, Calle EE, Thun MJ. Underuse of screening sigmoidoscopy and colonoscopy in a large cohort of US adults. Am J Public Health 2004 94:1775 81.
15. Colorectal cancer test use among persons aged > or = 50 years - United States, 2001. MMWR Morb Mortal Wkly Rep 2003 52:193 6.
16. Schroy PC, Heeren TC. A comparative study of patient perceptions and screening preferences for stool-based DNA testing (SBDNA), fecal occult blood testing (FOBT) or colonoscopy (CS) (Abstract). Gastroenterology 2003 124:A-77.
17. Schroy PC, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med 2005 28:208.
18. Berger BM, Schroy PC 3rd., Rosenberg JL, et al. Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests. Clin Colorectal Cancer 2006 5:338 43.
19. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology 2004 127:1661 9.
20. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared to conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004 126:1270 9.
21. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004 351:2704 14.
22. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 2005 129:1151 62.
23. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 2005 14:183.
24. Whitney D, Skoletsky J, Moore K, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004 6:386.
25. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004 127:1578.
26. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007 5:111 7.
27. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 65:671 80.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350:2335 42.
29. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003 21:2787 99.
30. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 351:337 45.
31. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004 351:317 9.
32. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993 328:1365 71.
33. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000 343:1603 7.
34. Bat L, Pines A, Ron E, Niv Y, Arditi E, Shemesh E. A community-based program of colorectal screening in an asymptomatic population: evaluation of screening tests and compliance. Am J Gastroenterol 1986 81:647 51.
35. Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the U.S. perspective. Am J Gastroenterol 2006 101:219 21.
36. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996 348:1472 7.
37. Ioannou GN, Chapko MK, Dominitz JA. Predictors of colorectal cancer screening participation in the United States. Am J Gastroenterol 2003 98:2082 91.
38. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996 348:1467 71.
39. Liang SY, Phillips KA, Nagamine M, Ladabaum U, Haas JS. Rates and predictors of colorectal cancer screening. Prev Chronic Dis 2006 3:A117.
40. Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev 2006 15:389 94.
41. Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA. A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg 1991 161:101 5 discussion 105-6.
42. Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L. Adherence to continuous screening for colorectal neoplasia. Med Care 1993 31:508 19.
43. Seeff LC, Nadel MR, Klabunde CN, et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004 100:2093 103.
44. Shapiro JA, Seeff LC, Nadel MR. Colorectal cancer-screening tests and associated health behaviors. Am J Prev Med 2001 21:132 7.
45. Ladabaum U, Song K, Fendrick AM. Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact? Clin Gastroenterol Hepatol 2004 2:554 63.
46. CMS Clinical Laboratory Fee Schedule. Available at: http://www.cms.hhs. gov/ClinicalLabFeeSched/02_clinlab.asp#TopOfPage, accessed on 19 April 2007.
47. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003 114:546 54.
48. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2006 4:808 21.
49. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 21:60 5.
50. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005 352:476 87.
51. Saltz LB, Meropol NJ, Loehrer PJ Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004 22:1201 8.
52. Life tables. In:Vital Statistics of the United States. Preprint of Vol. II, Mortality, Part A, Section 6. Hyattsville, MD:National Center for Health Statistics, 1998:Section 6, pp. 1 18.
53. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003 124:544 60.
54. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006 130:1872 85.
55. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003 53:27 43.
56. Allison JE. Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 2005 129:745 8.
57. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996 334:155 9.
58. Rozen P, Knaani J, Samuel Z. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia. Dig Dis Sci 1997 42:2064 71.
59. Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000 95:1331 8.
60. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005 129:422 8.
61. Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med 2003 115:111 4.
62. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999 46:228 31.
63. Rozen P, Knaani J, Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study. Cancer 2000 89:46 52.
64. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005 100:2519 25.
65. Wong BC, Wong WM, Cheung KL, et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003 18:941 6.
66. Young GP, St John DJ, Cole SR, et al. Prescreening evaluation of a brush-based faecal immunochemical test for haemoglobin. J Med Screen 2003 10:123 8.
67. Enterix Corporation. Available at: http://www.insuretest.com/ professionals/invitro.html, accessed on October 2006.
68. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 146:473 81.
69. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993 148:927 9.
70. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995 15:369 90.
71. Eddy DM, Nugent FW, Eddy JF, et al. Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology 1987 92:682 92.
72. The DRG Handbook: Comparative Clinical and Financial Standards. Baltimore, MD:HCIA, Inc. and Ernst & Young LLP, 1997.
73. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999 37:1249 59.
74. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997 18:51 76.
75. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995 87:417 26.
76. Greene FL. American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual, 6th edn. New York:Springer, 2002.
77. NCDB Site by Stage Distribution of Cancer - 2003. Available at: http://www.facs.org/cancer/ncdb/ver7_site_stage_2003.htm, accessed on 20 April 2007.
78. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004 22:23 30.
79. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin Oncol 2006 5 (Suppl. 10 S15 8.
80. U.S. Department of Labor, Bureau of Labor Statistics, Consumer Price Indexes, Available at: http://www.bls.gov/cpi/, accessed on 12 February 2008, accessed on 20 April 2007.
81. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In:Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY:Oxford University Press, 1996:214 35.
82. Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet 1989 1:1160 4.
83. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JDF. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000 92:557 63.
84. Ling BS, Moskowitz MA, Wachs D, Pearson B, Schroy PC. Attitudes toward colorectal cancer screening tests. J Gen Intern Med 2001 16:822 30.
85. Dominitz JA, Provenzale D. Patient preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol 1997 92:2171 8.
86. Leard LE, Savides TJ, Ganiats TG. Patient preferences for colorectal cancer screening. J Fam Pract 1997 45:211 8.
87. Nelson RL, Schwartz A. A survey of individual preference for colorectal cancer screening technique. BMC Cancer 2004 4:76.
88. Pignone M, Bucholtz D, Harris R. Patient preferences for colon cancer screening. J Gen Intern Med 1999 14:432 7.
89. Pignone M, Harris R, Kinsinger L. Videotape-based decision aid for colon cancer screening. A randomized, controlled trial. Ann Intern Med 2000 133:761 9.
90. Sheikh RA, Kapre S, Calof OM, Ward C, Raina A. Screening preferences for colorectal cancer: a patient demographic study. South Med J 2004 97:224 30.
91. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985 36:179 86.
92. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982 49:819 25.
93. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982 23:835 42.
94. Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 1964 19:249 61.
95. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 1979 43:1847 57.
96. Yee J, Akerkar GA, Hung RK, Steinauer-Gebauer AM, Wall SD, McQuaid KR. Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients. Radiology 2001 219:685 92.
97. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK (eds). SEER Cancer Statistics Review, 1973-1994, NIH Pub. No. 97-2789. Bethesda, MD:National Cancer Institute, 1997.
98. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993 329:1977 81.